All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL HubAML HubGVhD HubLymphoma HubMDS HubMPN Hub

The EMA CHMP provide positive opinion on cilta-cel for RRMM

Mar 30, 2022
Share:

On March 24, 2022, it was announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) provide a positive opinion for granting a conditional marketing authorization for the use of ciltacabtagene autoleucel (cilta-cel) for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM). The marketing authorization is for patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy.1

Cilta-cel is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy, which has recently been granted approval by the U.S. Food and Drug Administration (FDA) in this patient population based on results of the CARTITUDE-1 trial. Read more about this here.

  1. European Medicines Agency. Carvykti. https://www.ema.europa.eu/en/medicines/human/summaries-opinion/carvykti. Published, Mar 25, 2022. Accessed, Mar 29, 2022.

Share: